At WACKER BIOSOLUTIONS, sales were markedly higher in 2014. They rose 11.2 percent to € 176.2 million (2013: € 158.4 million). This growth was due to the integration of Halle-based Scil Proteins Production GmbH, which was consolidated for the first time in 2014, as well as to higher volumes and prices. Sales growth was impeded by slightly negative exchange-rate effects. Whereas food and pharmaceutical proteins performed well, the situation was somewhat more difficult in the pharmaceuticals and agrochemicals segment. WACKER BIOSOLUTIONS posted strong sales growth in the Americas (+28 percent) and Europe (+17 percent). In Asia, business declined year on year (-8 percent). At € 23.6 million, EBITDA in 2014 was on a par with the previous year (€ 23.6 million). The division’s EBITDA margin edged down to 13.4 percent (2013: 14.9 percent).

Investments declined compared with the previous year, amounting to € 8.4 million (2013: € 10.2 million). In early 2014, the division also acquired Scil Proteins Production GmbH for about € 14 million. Since this acquisition, WACKER BIOSOLUTIONS has had a fermenter with a capacity of 1,500 liters.

The number of employees at WACKER BIOSOLUTIONS rose to 484 as of December 31, 2014 (Dec. 31, 2013: 371), primarily due to the acquisition of Scil Proteins Production GmbH.

Key Data: WACKER BIOSOLUTIONS